Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Korean Medical Science"
DOI: 10.3346/jkms.2022.37.e335
Abstract: Background Non-vitamin K antagonist oral anticoagulants (NOACs) are effective in preventing thromboembolisms and reduce the risk of bleeding compared with warfarin. There are few reports on the outcomes of on-label reduced-dose NOACs. The aim of… read more here.
Keywords: label reduced; patients atrial; edoxaban patients; dose edoxaban ... See more keywords